Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | SI | P14410 | 2/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18271802 | 0.83 | TSHR (0.38) | TSHRSMN1; SMN2MGAMGAASI | |
| SCHEMBL27903539 | 0.81 | TSHR (0.39) | TSHRSMN1; SMN2 | |
| SCHEMBL27668406 | 0.81 | TSHR (0.37) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL27935662 | 0.81 | TSHR (0.39) | TSHRSMN1; SMN2 | |
| SCHEMBL12785257 | 0.81 | ALDH1A1 (0.37) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL19439578 | 0.80 | TSHR (0.53) | TSHRSMN1; SMN2HSD17B10CTSKPOLB | |
| SCHEMBL4748897 | 0.79 | TSHR (0.36) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL11352922 | 0.79 | TSHR (0.47) | TSHRSMN1; SMN2HSD17B10KDM4ECTSK | |
| SCHEMBL563304 | 0.78 | TSHR (0.34) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL17755804 | 0.78 | TSHR (0.34) | TSHRMGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383718-B1 | CONTINUOUS HYDROFORMYLATION PROCESS | DSM IP ASSETS BV (NL) | 2006-06-28 | — | — | EP | claimed |
| US-20040138508-A1 | Rapid, low temperature vacuum evaporator recovery of rhodium bisphosphite catalyst from high boiling point aldehydes without degradation | DSM I.P. ASSETS B.V. (NL) | 2004-07-15 | — | — | US | claimed |
| EP-1383718-A1 | CONTINUOUS HYDROFORMYLATION PROCESS | DSM IP Assets B.V. (NL) | 2004-01-28 | — | — | EP | claimed |
| WO-2002083605-A1 | CONTINUOUS HYDROFORMYLATION PROCESS | DSM IP ASSETS B.V. (NL) | 2002-10-24 | — | — | WO | claimed |
| US-6355831-B1 | CATALYTIC REACTION OF FORMYLVALERIC ESTER USING NOBLE METAL AS CATALYST | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2002-03-12 | — | — | US | claimed |
| EP-0295548-B1 | METHOD FOR THE PRODUCTION OF PENTENOIC ACID ESTERS FROM ESTERS OF FORMYL-VALERIC ACID | BASF Aktiengesellschaft (DE) | 1992-03-18 | — | — | EP | claimed |
| US-4879406-A | DEHYDROFORMYLATION | BASF AKTIENGESELLSCHAFT (DE) | 1989-11-07 | — | — | US | claimed |
| US-8912329-B2 | Composition for treatment of tuberculosis | BioVersys AG (CH) | 2014-12-16 | — | — | US | disclosed |
| EP-2445495-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | Bioversys AG (CH) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BioVersys AG (CH) | 2012-04-26 | — | — | US | disclosed |
| WO-2010149761-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BIOVERSYS GMBH (CH) | 2010-12-29 | — | — | WO | disclosed |
| CN-1328235-C | Improed process of prepn. of linear aldehydes | DU PONT (US) | 2007-07-25 | — | — | CN | disclosed |
| US-7202193-B2 | Process for the carbonylation of an ethylenically unsaturated compound and catalyst therefore | SHELL OIL COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| EP-0295551-B1 | METHOD FOR THE PRODUCTION OF ADIPIC ACID | BASF Aktiengesellschaft (DE) | 1993-04-14 | — | — | EP | disclosed |
| EP-0293748-B1 | PROCESS FOR THE PREPARATION OF 2(5H)-FURANONES | BASF Aktiengesellschaft (DE) | 1992-01-29 | — | — | EP | disclosed |
| US-4931590-A | Preparation of adipic acid | BASF AKTIENGESELLSCHAFT (DE) | 1990-06-05 | — | — | US | disclosed |
| US-4853473-A | Preparation of 2(5H)-furanones | BASF AKTIENGESELLSCHAFT (DE) | 1989-08-01 | — | — | US | disclosed |
| EP-0295549-A2 | Method for the production of 5-formyl valeric acid esters | BASF Aktiengesellschaft (DE) | 1988-12-21 | — | — | EP | disclosed |
| EP-0295551-A2 | Method for the production of adipic acid | BASF Aktiengesellschaft (DE) | 1988-12-21 | — | — | EP | disclosed |
| EP-0293748-A2 | Process for the preparation of 2(5H)-furanones | BASF Aktiengesellschaft (DE) | 1988-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | PRMT7, NCOA3, PRMT3 | TSHR 38/4885SMN1; SMN2 4154/4885MGAM 4275/4885 |
| US-20040138508-A1 | Rapid, low temperature vacuum evaporator recovery of rhodium bisphosphite catalyst from high boiling point aldehydes without degradation | VAPB, VAPA, MVD | TSHR 3352/4885SMN1; SMN2 2453/4885MGAM 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.